Characteristics of the study population at baseline and during follow-up (N = 22 929)
| Characteristic . | At baseline . | Occurrence during follow-up . |
|---|---|---|
| Socio-demographic characteristics | ||
| Age in years, mean (s.d.) | 43.0 (13.9) | |
| Male sex | 10 285 (44.9) | |
| French deprivation indexa, mean (s.d.) | 0.01 (0.93)b | |
| Complementary universal health coverage | 13 634 (59.5) | |
| Aid for complementary health coverage | 244 (1.1) | |
| State medical aid | 43 (0.2) | |
| Comorbidities | ||
| −Diabetes | 951 (4.2) | 821 (3.6) |
| −Hypertension | 3893 (17.0) | 2357 (10.3) |
| −Dyslipidaemia | 2269 (10.0) | 1145 (5.0) |
| −Smoking | 459 (2.0) | 661 (2.9) |
| −Obesity | 117 (0.5) | 338 (1.5) |
| −Chronic kidney disease | 57 (0.3) | 54 (0.2) |
| −Atherosclerosis of arteries of extremities | 127 (0.6) | 126 (0.6) |
| −Depression | 4731 (20.6) | 3137 (13.6) |
| Treatments | ||
| −NSAIDs | 19 633 (85.6) | 1822 (8.0) |
| −COX2-selective inhibitors | 3518 (15.3) | 3035 (13.2) |
| −Non-selective NSAIDs | 19 297 (84.2) | 1899 (8.3) |
| −MTX | 930 (4.1) | 3465 (15.1) |
| −LEF | 112 (0.5) | 366 (1.6) |
| −SSZ | 1760 (7.7) | 2079 (9.1) |
| −Anti-TNF | 1344 (5.9) | 9456 (41.2) |
| −Anti-IL17 | 0 | 1095 (4.8) |
| Characteristic . | At baseline . | Occurrence during follow-up . |
|---|---|---|
| Socio-demographic characteristics | ||
| Age in years, mean (s.d.) | 43.0 (13.9) | |
| Male sex | 10 285 (44.9) | |
| French deprivation indexa, mean (s.d.) | 0.01 (0.93)b | |
| Complementary universal health coverage | 13 634 (59.5) | |
| Aid for complementary health coverage | 244 (1.1) | |
| State medical aid | 43 (0.2) | |
| Comorbidities | ||
| −Diabetes | 951 (4.2) | 821 (3.6) |
| −Hypertension | 3893 (17.0) | 2357 (10.3) |
| −Dyslipidaemia | 2269 (10.0) | 1145 (5.0) |
| −Smoking | 459 (2.0) | 661 (2.9) |
| −Obesity | 117 (0.5) | 338 (1.5) |
| −Chronic kidney disease | 57 (0.3) | 54 (0.2) |
| −Atherosclerosis of arteries of extremities | 127 (0.6) | 126 (0.6) |
| −Depression | 4731 (20.6) | 3137 (13.6) |
| Treatments | ||
| −NSAIDs | 19 633 (85.6) | 1822 (8.0) |
| −COX2-selective inhibitors | 3518 (15.3) | 3035 (13.2) |
| −Non-selective NSAIDs | 19 297 (84.2) | 1899 (8.3) |
| −MTX | 930 (4.1) | 3465 (15.1) |
| −LEF | 112 (0.5) | 366 (1.6) |
| −SSZ | 1760 (7.7) | 2079 (9.1) |
| −Anti-TNF | 1344 (5.9) | 9456 (41.2) |
| −Anti-IL17 | 0 | 1095 (4.8) |
Characteristics of the study population at baseline and during follow-up (N = 22 929)
| Characteristic . | At baseline . | Occurrence during follow-up . |
|---|---|---|
| Socio-demographic characteristics | ||
| Age in years, mean (s.d.) | 43.0 (13.9) | |
| Male sex | 10 285 (44.9) | |
| French deprivation indexa, mean (s.d.) | 0.01 (0.93)b | |
| Complementary universal health coverage | 13 634 (59.5) | |
| Aid for complementary health coverage | 244 (1.1) | |
| State medical aid | 43 (0.2) | |
| Comorbidities | ||
| −Diabetes | 951 (4.2) | 821 (3.6) |
| −Hypertension | 3893 (17.0) | 2357 (10.3) |
| −Dyslipidaemia | 2269 (10.0) | 1145 (5.0) |
| −Smoking | 459 (2.0) | 661 (2.9) |
| −Obesity | 117 (0.5) | 338 (1.5) |
| −Chronic kidney disease | 57 (0.3) | 54 (0.2) |
| −Atherosclerosis of arteries of extremities | 127 (0.6) | 126 (0.6) |
| −Depression | 4731 (20.6) | 3137 (13.6) |
| Treatments | ||
| −NSAIDs | 19 633 (85.6) | 1822 (8.0) |
| −COX2-selective inhibitors | 3518 (15.3) | 3035 (13.2) |
| −Non-selective NSAIDs | 19 297 (84.2) | 1899 (8.3) |
| −MTX | 930 (4.1) | 3465 (15.1) |
| −LEF | 112 (0.5) | 366 (1.6) |
| −SSZ | 1760 (7.7) | 2079 (9.1) |
| −Anti-TNF | 1344 (5.9) | 9456 (41.2) |
| −Anti-IL17 | 0 | 1095 (4.8) |
| Characteristic . | At baseline . | Occurrence during follow-up . |
|---|---|---|
| Socio-demographic characteristics | ||
| Age in years, mean (s.d.) | 43.0 (13.9) | |
| Male sex | 10 285 (44.9) | |
| French deprivation indexa, mean (s.d.) | 0.01 (0.93)b | |
| Complementary universal health coverage | 13 634 (59.5) | |
| Aid for complementary health coverage | 244 (1.1) | |
| State medical aid | 43 (0.2) | |
| Comorbidities | ||
| −Diabetes | 951 (4.2) | 821 (3.6) |
| −Hypertension | 3893 (17.0) | 2357 (10.3) |
| −Dyslipidaemia | 2269 (10.0) | 1145 (5.0) |
| −Smoking | 459 (2.0) | 661 (2.9) |
| −Obesity | 117 (0.5) | 338 (1.5) |
| −Chronic kidney disease | 57 (0.3) | 54 (0.2) |
| −Atherosclerosis of arteries of extremities | 127 (0.6) | 126 (0.6) |
| −Depression | 4731 (20.6) | 3137 (13.6) |
| Treatments | ||
| −NSAIDs | 19 633 (85.6) | 1822 (8.0) |
| −COX2-selective inhibitors | 3518 (15.3) | 3035 (13.2) |
| −Non-selective NSAIDs | 19 297 (84.2) | 1899 (8.3) |
| −MTX | 930 (4.1) | 3465 (15.1) |
| −LEF | 112 (0.5) | 366 (1.6) |
| −SSZ | 1760 (7.7) | 2079 (9.1) |
| −Anti-TNF | 1344 (5.9) | 9456 (41.2) |
| −Anti-IL17 | 0 | 1095 (4.8) |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
